| REGISTERED NUMBER: |
| Financial Statements |
| for the Year Ended 31 December 2024 |
| for |
| Bio Scope Technologies Ltd |
| REGISTERED NUMBER: |
| Financial Statements |
| for the Year Ended 31 December 2024 |
| for |
| Bio Scope Technologies Ltd |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Contents of the Financial Statements |
| for the Year Ended 31 December 2024 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 3 |
| Bio Scope Technologies Ltd |
| Company Information |
| for the Year Ended 31 December 2024 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| SENIOR STATUTORY AUDITOR: |
| AUDITORS: |
| Eldo House |
| Kempson Way |
| Suffolk Business Park |
| Bury St Edmunds |
| Suffolk |
| IP32 7AR |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Balance Sheet |
| 31 December 2024 |
| 2024 | 2023 |
| as restated |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Tangible assets | 4 |
| CURRENT ASSETS |
| Stocks |
| Debtors | 5 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 6 |
| NET CURRENT LIABILITIES | ( |
) | ( |
) |
| TOTAL ASSETS LESS CURRENT LIABILITIES | ( |
) | ( |
) |
| CAPITAL AND RESERVES |
| Called up share capital | 8 |
| Share premium |
| Retained earnings | ( |
) | (2,729,352 | ) |
| SHAREHOLDERS' FUNDS | ( |
) | ( |
) |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Notes to the Financial Statements |
| for the Year Ended 31 December 2024 |
| 1. | STATUTORY INFORMATION |
| Bio Scope Technologies Ltd is a |
| The presentation currency of the financial statements is the Pound Sterling (£). |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Going Concern |
| Having reviewed the projected results and cash flow forecasts of the company the directors are confident that the company will be able to meet its cash obligations in the foreseeable future. |
| The company is in an intensive phase of research and development that brings a requirement for funds in addition to that needed for day to day trading. This funding has been provided in the year by the directors, shareholders and the parent company via both capital and loan funding. The company has the continued support of these stakeholders, who are committed to supporting the company as necessary through this phase. |
| The directors are therefore confident that the cash demands of the company will be satisfied, and it is therefore appropriate to prepare the financial statements on the going concern basis. |
| Related party exemption |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Turnover represents the sales value of work completed at the balance sheet date excluding VAT. The Company's contractual obligations are performed over time therefore revenue is recognised as the contract activity progresses to reflect the Company's partial performance of its contractual obligations. Revenue is calculated by reference to the value of work performed. |
| Tangible fixed assets |
| Leasehold property | - |
| Plant and machinery | - |
| Equipment | - |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Stocks |
| There are different types of stock that the company hold which are valued as follows: |
| Recycling material |
| This is weighed at year-end and valued at cost per kilogram. |
| Work In Progress |
| Recycling material that is part way through the refining process is weighed at the year end, and a cost applied based on the original cost of the recycling material being processed. This cost does not include the cost of the processing or any overhead absorption. |
| Finished Goods |
| Any finished goods that consists of fully processed material is weighed at year-end and a conservative scrap material price is used based on the current London Metal Exchange prices. |
| Taxation |
| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
| Current or deferred taxation assets and liabilities are not discounted. |
| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
| Deferred tax |
| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
| Research and development |
| Expenditure on research and development is written off in the year in which it is incurred. |
| Hire purchase and leasing commitments |
| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
| Pension costs and other post-retirement benefits |
| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Impairment |
| At each reporting date, goodwill and other fixed assets, including tangible fixed assets and investments but excluding investment properties, are assessed to determine whether there is an indication that the carrying amount of an asset may be more than its recoverable amount and that the asset should be impaired. If there is an indication of possible impairment, the recoverable amount of an asset, which is the higher of its value in use and its net realisable value, is estimated and compared with its carrying amount. If the recoverable amount is lower, the carrying amount of the asset is written down to its estimated recoverable amount and an impairment loss is recognised in profit and loss. |
| 3. | EMPLOYEES AND DIRECTORS |
| The average number of employees during the year was |
| 4. | TANGIBLE FIXED ASSETS |
| Plant and |
| machinery |
| etc |
| £ |
| COST |
| At 1 January 2024 |
| Additions |
| At 31 December 2024 |
| DEPRECIATION |
| At 1 January 2024 |
| Charge for year |
| At 31 December 2024 |
| NET BOOK VALUE |
| At 31 December 2024 |
| At 31 December 2023 |
| 5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2024 | 2023 |
| as restated |
| £ | £ |
| Trade debtors |
| Other debtors |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2024 | 2023 |
| as restated |
| £ | £ |
| Trade creditors |
| Amounts owed to group undertakings |
| Taxation and social security |
| Other creditors |
| 7. | LEASING AGREEMENTS |
| Minimum lease payments under non-cancellable operating leases fall due as follows: |
| 2024 | 2023 |
| as restated |
| £ | £ |
| Within one year |
| Between one and five years |
| 8. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2024 | 2023 |
| value: | as restated |
| £ | £ |
| Ordinary | £1 | - | 100 |
| Ordinary | £0.01 | 150 | - |
| 150 | 100 |
| On 8 May 2024 the existing class of 100 Ordinary Shares of £1 each were subdivided into 10,000 Ordinary Shares of £0.01 each . |
| On 8 May 2024 4,950 Ordinary Shares of £0.01 each were issued for consideration of £200 per share which amounts to £990,000. |
| On 18 February 2025 7,000 Ordinary Shares of £0.01 each were issued for consideration of £200 per share which amounts to £1,400,000. |
| 9. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006 |
| The Report of the Auditors was unqualified. |
| for and on behalf of |
| Bio Scope Technologies Ltd (Registered number: 13876617) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 December 2024 |
| 10. | PENSION COMMITMENTS |
| The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £28,936 (2023 £34,454). Contributions totalling £4,789 (2023 £Nil) were payable to the fund at the balance sheet date and included in creditors. |
| 11. | CAPITAL COMMITMENTS |
| 2024 | 2023 |
| as restated |
| £ | £ |
| Contracted but not provided for in the |
| financial statements |
| 12. | RELATED PARTY DISCLOSURES |
| During the year, a debt for equity swap took place where debt in Bio Scop 3 Ltd was converted to equity in Bio Scope Technologies Ltd. See note 10 for details. |
| 13. | ULTIMATE CONTROLLING PARTY |
| The immediate and ultimate parent undertaking is Bio Scope 3 Ltd. |
| There are no individual controlling parties. |
| 14. | SHARE-BASED PAYMENT TRANSACTIONS |
| The company operates an Unapproved Share Scheme under which share options were granted to employees to incentivise and retain key staff. |
| Options vest upon an exit event. They lapse if the employee resigns or are dismissed. |
| The fair value of the options granted has been measured at the grant date and will be accounted for in accordance with Section 26 of FRS 102 - Share-based Payment. The share-based payment expense will be recognised in the profit and loss account over the vesting period. |
| As there is currently no reliable basis to determine a probable valuation or timing of a vesting date, no expense has been recognised in the current year. The total recognised expense for the current year is £nil. |